Low BMI-1 expression is associated with an activated BMI-1-driven signature, vascular invasion, and hormone receptor loss in endometrial carcinoma

Por Engelsen, I B, Mannelqvist, M, Stefansson, I M, Carter, S L, Beroukhim, R, Øyan, A M, Otte, A P, Kalland, K H, Akslen, L A, Salvesen, H B
Publicado em 2008

High BMI is significantly associated with positive progesterone receptor status and clinico-pathological markers for non-aggressive disease in endometrial cancer

Por Mauland, K K, Trovik, J, Wik, E, Raeder, M B, Njølstad, T S, Stefansson, I M, Øyan, A M, Kalland, K H, Bjørge, T, Akslen, L A, Salvesen, H B
Publicado em 2011

Loss of GPER identifies new targets for therapy among a subgroup of ERα-positive endometrial cancer patients with poor outcome

Por Krakstad, C, Trovik, J, Wik, E, Engelsen, I B, Werner, H M J, Birkeland, E, Raeder, M B, Øyan, A M, Stefansson, I M, Kalland, K H, Akslen, L A, Salvesen, H B
Publicado em 2012

Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation

Por Salvesen, H. B., Carter, S. L., Mannelqvist, M., Dutt, A., Getz, G., Stefansson, I. M., Raeder, M. B., Sos, M. L., Engelsen, I. B., Trovik, J., Wik, E., Greulich, H., Bø, T. H., Jonassen, I., Thomas, R. K., Zander, T., Garraway, L. A., Øyan, A. M., Sellers, W. R., Kalland, K. H., Meyerson, M., Akslen, L. A., Beroukhim, R.
Publicado em 2009